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ABSTRACT A three-dimensional model structure of a complex formed by a G-protein-coupled receptor (GPCR) and an ag-
onist ligand is probed and reﬁned using molecular-dynamics simulations and free energy calculations in a realistic environment.
The model of the human receptor of cholecystokinin associated to agonist ligand CCK9 was obtained from a synergistic pro-
cedure combining site-directed mutagenesis experiments and in silico modeling. The 31-ns molecular-dynamics simulation in
an explicit membrane environment indicates that both the structure of the receptor and its interactions with the ligand are robust.
Whereas the secondary structure of the a-helix bundle is well preserved, the region of the intracellular loops exhibits a
signiﬁcant ﬂexibility likely to be ascribed to the absence of G-protein subunits in the model. New insight into the structural
features of the binding pocket is gained, in particular, the interplay of the ligand with both the receptor and internal water
molecules. Water-mediated interactions are shown to participate in the binding, hence, suggesting additional site-directed
mutagenesis experiments. Accurate free energy calculations on mutated ligands provide differences in the receptor-ligand
binding afﬁnity, thus offering a direct, quantitative comparison to experiment. We propose that this detailed consistency-
checking procedure be used as a routine reﬁnement step of in vacuo GPCR models, before further investigation and application
to structure-based drug design.
INTRODUCTION
One of the grand challenges amenable to molecular model-
ing is to provide a microscopic insight into membrane pro-
teins when conventional experimental techniques are not able
to supply this level of information. Of particular interest are
seven transmembrane (TM) domain G-protein-coupled re-
ceptors (GPCRs) (1), which correspond to the third largest
family of genes in the human genome (2,3), and constitute
key targets for de novo drug design (4). Alone, molecular
modeling is unlikely to reach the atomic detail hitherto inac-
cessible to experiment, but is anticipated to help interpret-
ing inferences accrued in recent years from the wealth of
structure-activity data available for GPCRs, thereby improv-
ing our understanding of their ontogeny and function (5).
Resolution of the three-dimensional structure of bovine rho-
dopsin (6), the only high-resolution GPCR structure deter-
mined by x-ray crystallography to this date, has opened new
prospects for the modeling of structurally related membrane
proteins, by providing valuable guidelines against which
original theoretical hypotheses can be confronted (7,8). Unfor-
tunately, these guidelines suffer severe limitations rooted
in the conformation in which rhodopsin was crystallized,
namely, the inactive, dark state of the receptor, recognized in
some instances to be an unsuitable template for activated
complexes formed by a GPCR and an agonist ligand (9–11).
In the past ﬁve years, much effort has been invested in the
prediction of the structure and function of GPCRs, employ-
ing molecular modeling tools ranging from ﬁrst principles
(12,13) to knowledge-based methods (7,14,15). In the ﬁrst
class of approaches, the individually predicted and optimized
TM helical segments of the modeled GPCR are packed using
a template of known structure, usually rhodopsin or, in
earlier investigations, bacteriorhodopsin. The second class of
approaches corresponds to a homology modeling relying
upon the crystallographic structure of a reasonably related
receptor, together with available experimental information.
In practice, such schemes are restricted to the rhodopsin
template and, consequently, suffer from its inherent limita-
tions when targeting activated receptors. An alternative to
the latter methods consists of a fully physics-based confor-
mational search using well-identiﬁed TM sequences, thereby
obviating the need for a template of known structure (16).
Molecular constructs resulting from knowledge-based ap-
proaches can be employed advantageously to design site-
directed mutagenesis experiments, which, in turn, can serve
to reﬁne the models and understand the function of the re-
ceptor. A recent contribution (17) combines experimental and
theoretical approaches in a self-consistent fashion, to model
the human receptor of cholecystokinin (CCK) (18). CCK is
ubiquitous to the gastrointestinal and central nervous sys-
tems, where it acts as a hormone and a neurotransmitter,
respectively. Control of satiety, gallbladder contraction, pan-
creatic exocrine secretions, gastric emptying, and gut motility
constitute pivotal actions of CCK that are mediated by the
so-called CCK1 receptor (CCK1R). The modeled complex
is formed by CCK1R and an agonist ligand (17), the
nonapeptide (Met, Nle)-CCK9, an analog of the endogenous
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ligand with the sequence Arg-Asp-S-Tyr-Thr-Gly-Trp-Met-
Asp-Phe-NH2—referred to as CCK9 in what follows. The
effort that ultimately yielded this model structure involved
a synergy between experiments and modeling (11,19–24).
Two-dimensional mutagenesis experiments guided the re-
ﬁnement of the model, which in turn highlighted possible
interactions and led to the design of additional mutants,
thereby offering a cross-validation and complementarity be-
tween experimental and theoretical information.
Despite the constraining framework of experimental data,
the proposed structure remains an in vacuo model, which
does not offer any guarantee of consistency with the physical
conditions of a membrane environment. Furthermore, inter-
pretation of binding-afﬁnity assays in terms of well-localized
interactions, only constitute an indirect link between the
model and experimental evidence. The route chosen here to
probe the behavior of the CCK1R model consists in per-
forming molecular dynamics and free energy simulations in
a realistic hydrated lipid bilayer. Achieving a good level of
consistency between simulated and measured properties
should increase the degree of conﬁdence in the structure when
it is used in docking studies aimed at screening potentially
active ligands. Noteworthily, screening alone has been ap-
plied to appraise the reliability of GPCR models (7,25,26).
Docking procedures have also been used to predict binding
modes in GPCR models and estimate receptor-ligand afﬁn-
ities (12). The strong dependence of molecular docking to
the scoring functions, however, makes it less reliable than
free-energy calculations. The signiﬁcant computational ef-
fort involved in free energy calculations explains why, hitherto,
the latter have not been applied to theoretical models of
receptor-ligand assemblies, in particular to those only par-
tially validated. Molecular dynamics (MD) simulations in an
explicit water-membrane environment have, however, been
employed in a handful of instances to probe the structure of
GPCRs, either the prototypical rhodopsin (27), or models of
not-yet-resolved three-dimensional structures, like the CXCR4
(28), the m-opioid (29), or the d-opioid (30) receptor.
In this article, large-scale molecular dynamics simulations
are used to probe and reﬁne the model of CCK1R:CCK9
when embedded in a lipid bilayer, with particular attention to
the conservation of the experimental constraints. In addition,
this step provides an insight into the interplay of the receptor-
ligand complex with the explicit molecules forming its envi-
ronment, which are clearly absent from the in vacuo construct.
Next, a direct, quantitative criterion for comparison to ex-
periment is obtained through free energy calculations targeted
at reproducing relative binding afﬁnities measured for mutated
ligands. Such alchemical transformations are employed for
the ﬁrst time to close-the-loop of the modeling process of a
GPCR, by reproducing in silico the experimental binding
afﬁnities that were utilized to guide its construction. The point
mutations chosen here correspond to the replacement of sul-
fated tyrosine S-Tyr-3 by a tyrosyl residue and of Asp-8 by
alanine—namely, the third and penultimate amino acids at the
N- and the C-termini of CCK9, respectively interacting with
the extracellular loop and buried in the binding pocket. Se-
lection of these transformations was dictated by the limited
magnitude of the structural changes in the agonist ligand and, a
priori, in the receptor, and the necessity of marked differences
in the binding afﬁnities, compatible with the level of accu-
racy currently attained by free energy calculations (31). Alanine
replacement of Asp-8 at the C-terminus of CCK9 and
removal of the sulfate moiety of S-Tyr-3 at the N-terminus
have been demonstrated to yield a signiﬁcant decrease in the
binding afﬁnity of CCK9 toward CCK1R (20–23). Further-
more, the two mutated ligands retain the biological activity
of the agonist (23). Mutations in the bound state are, there-
fore, not expected to entail an allosteric transition of the re-
ceptor, which would occur over timescales exceeding those
accessible to all-atom MD simulations.
METHODS
Description of the system
Considering that the ﬁrst residues of CCK1R do not play any particular role
on binding afﬁnities (19), it was chosen to truncate the native sequence of
376 amino acids at its N-terminus, resulting in a model of the receptor that
consists of 345 residues. The receptor-ligand complex was embedded in a
fully hydrated palmitoyloleoylphosphatidylcholine (POPC) bilayer. Ini-
tially, the receptor-ligand complex was positioned across the equilibrated
bilayer, while seeking to match the hydrophobic protein segments with the
layer formed by the lipid hydrocarbon tails. Lipids overlapping with the
protein complex were deleted, leaving a bilayer consisting of 228 POPC
molecules. To ascertain that the cytoplasmic and extracellular loops do not
interact, an amount of 16,527 water molecules was added, as well as 24
chloride counterions to compensate for the positive net charge of the protein,
thus making a total number of atoms equal to 72,255. The complete system,
represented in Fig. 1, was replicated periodically in the three directions of
space, with a vertical repeat distance of ;115 A˚. For the simulation of the
ligand in aqueous medium, the solvent box contained 4120 water molecules,
one chloride and two sodium counterions.
Molecular dynamics simulations
A 31-ns MD simulation was carried out in the isobaric-isothermal ensemble,
maintaining the pressure and the temperature at 1.0 atm and 300.0 K,
respectively, by means of Langevin dynamics and the Langevin piston
approach. The MD program NAMD (32,33) was employed in conjunction
with the CHARMM27 force ﬁeld (34) to describe the receptor, the agonist
ligand, the lipid bilayer, and the water molecules. Since the sulfated tyrosine
residue is not described in the standard force ﬁeld, new dihedral angle
parameters were computed and a set of point charges was derived from the
molecular electrostatic potential. This parameterization step was based on ab
initio calculations at the RHF/6-31G* level. A united-atom description of the
alkyl chains of the lipid molecules was utilized. Coulomb forces were
evaluated with the particle-mesh Ewald method. The equations of motion
were integrated with a 2-fs time step, using the r-RESPA algorithm to update
short- and long-range contributions at different frequencies.
Free energy calculations of
alchemical transformations
Direct insertion of the agonist ligand in the binding site of the protein by
means of a potential of mean-force-like calculation, which would yield an
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absolute free energy of association, still remains out of reach for current MD
simulations, on account of the slow relaxation of the collective degrees of
freedom in the membrane protein and its surroundings. To circumvent this
difﬁculty, for both the Asp-8 to Ala and the S-Tyr-3 to Tyr transformations,
free energy differences were computed between two distinct ligands—the
wild-type (CCK9), and the mutant—both in the free state, i.e., in an aqueous
environment, and bound to the receptor, as depicted in the thermodynamic
cycle of Fig. 1. Point mutations in bulk water and in the receptor were
performed employing the free energy perturbation (FEP) method (35),
wherein the Gibbs free energy difference between two thermodynamic states
connected by M intermediate, nonphysical substates is expressed as
DG ¼ 1
b
+
M1 1
i¼1
lnÆexpfb½Vðx; li1 1Þ  Vðx; liÞgæli ;
b ¼ 1=kBT;
where kB is the Boltzmann constant, T, the temperature; and Vðx;liÞ; the
potential energy function that depends upon the Cartesian coordinates of
the system {x}, and the coupling parameter, li, that connects the initial and
the ﬁnal states of the transformation. Considering the nature of the point
mutations, namely, neutralization of a charged amino acid, it was chosen to
break the reaction path into 114 stages of uneven widths. Narrow inter-
mediate states were deﬁned toward the end points of the simulation to avoid
singularities due to ignited interactions of an appearing moiety with its
environment. Each transformation, either in bulk water or in CCK1R (see
Fig. 1), was run for 3.4 ns. The dual-topology paradigm was utilized,
wherein the initial and the ﬁnal states are deﬁned concomitantly, but do
not interact (36). Simulations of CCK9 in water included a small number of
explicit counterions, which may lead to severe convergence issues in
free energy calculations (37). This was alleviated by enforcing harmonic
positional restraints on the sodium and chloride ions. Alchemical transfor-
mations involved both a negatively charged side chain and a sodium coun-
terion, so that the overall charge of the system was zero throughout the
transformation.
Estimation of errors in free energy calculations is usually difﬁcult and
presupposes stringent underlying approximations. It has been chosen to
provide an estimate of the error based on 1), carrying out the same alche-
mical transformations twice, after 5.0 and 10.5 ns of MD trajectory; and 2), a
ﬁrst-order expansion of the free energy,
DG ¼ 1
b
lnfÆexp½bDVðx; lÞæl6 deg;
where de is the statistical error on the ensemble average, Æexp bDVðx;lÞ½ æl;
expressed as
de2 ¼ 11 2t
N
fÆexp½2bDVðx; lÞæl Æexp½bDVðx;lÞæ2lg:
Here, N is the number of samples accrued in the FEP calculation, and
(1 1 2t) is the sampling ratio of the latter (38). Assuming that de is
appreciably smaller than Æexp½bDVðx; lÞæl; the free energy change can be
written at the ﬁrst-order as
DG ¼ 1
b
lnÆexp½bDVðx; lÞæl6
de
Æexp½bDVðx; lÞæl
 
:
FIGURE 1 (A) Front view of the assembly formed by CCK1R and CCK9
in an hydrated POPC bilayer. The a- and 310-helices are represented as
purple and pink ribbons, respectively. Coils and b-turns are shown as white
and cyan tubes. CCK9 is depicted as van der Waals spheres. P- and N-atoms
of the POPC headgroups are highlighted as orange and green spheres,
respectively. Atoms of water molecules are shown as van der Waals spheres.
Lipid chains are represented as cyan rods. Image rendering was obtained
with VMD (53). (B) Thermodynamic cycle used for the alchemical
transformations of the wild-type (WT) ligand CCK9 in the free, hydrated
state (left) and in the bound state (right). The values DG1bind and DG
2
bind are
determined experimentally. The free energy difference between the WT and
mutant ligands is given by DG2bind  DG1bind ¼ DG2mut  DG1mut: (C) Sec-
ondary structure of CCK1R as a function of time (top). The color scheme for
a- and 310-helices, b-turns, and coils follows the same conventions as a.
Roman numerals on the right-hand side indicate the TM helix number.
Distance RMSD (a-carbon atoms only) of various components of the system
with respect to the initial structure, as a function of time (bottom). The time
axis is common to both graphs.
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Binding-afﬁnity assays
New afﬁnity measurements of CCK9 analogs toward CCK1R were carried
out in order to provide reﬁned binding free energies with an increased
statistical conﬁdence over the ones published previously (21,22). The
binding afﬁnities were estimated by measuring in vitro the radioactivity of
transfected cells expressing the receptor, after exposure to radio-labeled
ligands. Nonapeptides were synthesized as described in previous reports
(39,40). 125INa was obtained from Pharmacia-Amersham (Les Ulis, France).
The CCK9 analogs were conjugated with the Bolton-Hunter reagent,
puriﬁed and radioiodinated, as described in Fourmy et al. (41). The speciﬁc
activity of the radioiodinated peptide was 1600–2000 Ci/mmol. All other
chemicals were obtained from commercial sources. COS-7 cells (1.53 106)
were plated onto 10-cm culture dishes and grown in Dulbecco’s modiﬁed
Eagle’s medium containing 5% of fetal calf serum in a 5% CO2 atmosphere,
at 37C. After overnight incubation, cells were transfected with 2.5 g/plate
of pRFENeo vectors containing the cDNA for the wild-type (WT) receptor,
using a modiﬁed DEAE-dextran method. Cells were then transferred onto
24-well plates at a density of 80,000 to 150,000 cells/well, 24 h after
transfection. Approximately 24 hours after the transfer, the cells were
washed with pH 6.95, 0.1% BSA phosphate buffer and then incubated for
60 min at 37C in 0.5 ml of Dulbecco’s modiﬁed Eagle’s medium, 0.1%
BSA with either 71 pM 125I-BH-(Thr, Nle)-CCK9 in the presence or the ab-
sence of competing compounds. Nonspeciﬁc binding was determined in the
presence of 1 mM ligand. The cells were washed twice with cold, 2% BSA
phosphate buffer, and the cell-associated radioligand was collected with 0.1M
NaOH added to each well. The radioactivity was directly counted using a
g-counter.
RESULTS AND DISCUSSION
Molecular dynamics simulation in a
membrane environment
To probe the intrinsic stability and the dynamic behavior of
the assembly built in vacuo and formed by CCK1R and the
agonist ligand CCK9 (17), the complete model was inserted
in a POPC bilayer and a 31-ns MD trajectory was generated.
The slow rearrangement of the aliphatic chains around the
receptor, occurring on the nanosecond timescale, is reﬂected
in a moderate contraction of the simulation cell in the plane
of the lipid membrane. Beyond ;5 ns, ﬂuctuations of the
dimensions of the system and in its total energy are suf-
ﬁciently limited to assume safely that an equilibrium has
been reached. Short, subnanosecond MD simulations that are
incompatible with the timescale of the organization of lipid
molecules near the receptor, should, therefore, be interpreted
with particular care.
The distance root mean-square deviation (RMSD) shown
in Fig. 1, computed using the backbone atoms of the integral
a-helices, with respect to the in vacuo construct, remains
close to 2.0 A˚ over the ﬁrst 20 ns, before increasing to ;2.5
A˚ in the remaining 11 ns, thereby highlighting the slow
relaxation of the collective degrees of freedom in the TM
domain. Deconvolution of the RMSD reveals an initial
greater disorder on the cytoplasmic side of the membrane,
the extracellular loops being partially structured by the
ligand protruding from the binding site. Considering that the
positioning of the intra- and extracellular loops has been
performed in vacuo, based on a limited amount of experi-
mental data, and, more importantly, in the absence of the
G-protein subunits, signiﬁcant rearrangement is to be expected
when immersed in a solvent. As has been underlined pre-
viously, failure to take into account the environment of the
loop region in an appropriate fashion may entail severe dis-
tortions in the structure of the receptor (42). A closer inspection
of the MD trajectory reveals that, on account of the structural
ﬂuctuations in the intracellular loops, the cytoplasmic end of
the a-helices is prone to depart from the initial construct. In
sharp contrast, the remainder of the TMdomain is well anchored
around the binding site and does not undergo noticeable struc-
tural modiﬁcations.
Secondary structure analysis of the complete protein (Fig.
1) indicates that the a-helical motifs in the TM region are
well conserved throughout the trajectory. Though ﬂexible,
the core of CCK9 is found predominantly in a b-turn con-
formation (43), in line with solution NMR analyses, which
suggest a dynamic equilibrium between ordered structures
(44,45).
Stability of the a-helix bundle over the simulated time-
scale indicates that the system has evolved around the same
local energy minimum. One should note, however, that, seem-
ingly stable structures in the gas phase are not necessarily
local energy minima of the molecular assembly formed by
the protein inserted in a water-lipid bilayer arrangement.
Besides, speaking of stability in vacuo is often equivocal,
considering that in the absence of appropriately chosen con-
straints, disruption of the tertiary structure may rapidly occur.
The essential of the key protein-ligand interactions brought
to light experimentally are preserved throughout the simu-
lation (see Fig. 2 A). Of particular interest, a network of
hydrophobic residues of CCK1R, that includes Leu-53, Val-
125, Ile-329, and Ile-352, appears to participate in favorable
van der Waals contacts with amino acids Met-7 and Phe-9 of
the agonist ligand (24). In addition, the strong electrostatic
interactions of Arg-336 with Asp-8 (22), and of Met-195 and
Arg-197 with the sulfated tyrosine S-Tyr-3, are equally well
conserved (21,23). Photoafﬁnity labeling experiments also
conﬁrm the direct interaction of Arg-197 with the sulfated
tyrosyl residue of the agonist ligand (46). Most importantly,
NMR investigations of CCK interacting with a fragment of
CCK1R that encompasses the top region of TM helix VI and
the third extracellular loop further supports the present
docking mode (44), hence casting doubt on the conjecture of
a reverted ligand that would interact with Trp-39 at its
C-terminus (43,47,48).
Mobility of the N-terminal segment of the receptor causes
a loss of contacts between Trp-39 and Gln-40 with the
N-terminus of CCK9 (20), substituted by a hydration shell. It
is legitimate to wonder whether this loss of interactions
results from the low speciﬁcity of the latter, or is a reﬂection
of a local ﬂaw in the model. Site-directed mutagenesis of
amino acids Trp-39 and Gln-40 leads to an increase in the
dissociation constant, Kd, ,20-fold (20). For comparison
purposes, replacement of Arg-336 by methionine corresponds
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to an increase of Kd by a factor ;118, thus suggesting that
receptor-ligand interactions in the N-terminal region of
CCK1R play an appreciably lesser role in the binding of
CCK9 (22).
The use of an explicit bilayer environment may also be
viewed as an enhancement to the model, as it grants access to
a detailed view of molecular interactions involving solvent
molecules. The binding pocket of CCK1R is sufﬁciently
wide to allow water molecules from the bulk to ﬂow in and
interact with the agonist ligand, which is consistent with
previous observations in bacteriorhodopsin (49). Whereas
hydration of CCK9 is substantial at its N-terminus, in the
region of the extracellular loops, water molecules become
scarce as the peptide is buried deeper in the receptor and are
conﬁned in a well-localized pocket that contains an average
of 25 molecules and communicates with the bulk (see Fig. 2
B). This water cluster, obviously absent in the original gas
phase model, progressively forms in the cavity over a period
of 3 ns, concomitantly with the creation of a passageway
between TM helices III and IV. Residence times for
molecules near the C-terminus of CCK9 may exceed the
nanosecond timescale, in sharp contrast with those located
higher in the crevice. Near the extracellular loops, water
molecules follow a diffusive regime and exchange rapidly
with the bulk aqueous medium. It should be noted that
internal water molecules do not disrupt the key receptor-
ligand interactions brought to light experimentally, but
instead, ﬁll available vacuities and solvate moieties of the
ligand that are not interacting directly with CCK1R (see
Fig. 2 A).
The direct receptor-ligand interactions, which constitute
the scaffold of the CCK1R:CCK9 association, are only
elements of the complete binding mode. Several indirect
interactions, relayed by water molecules, also appear to
participate in the binding. At the C-terminal of CCK9, the
amino group of Phe-9 interacts with the neighboring Thr-117
and Thr-118 residues through a single bridging water
molecule (see Fig. 2 C). Further up, the indole NH group
of Trp-6 interacts with Phe-107 by means of a bridged water
molecule, and the carbonyl group of Gly-5 interacts with the
hydroxyl moiety of Thr-117 relayed by a water molecule. A
water molecule pertaining to the aqueous pocket depicted in
Fig. 2 B connects Thr-4 to Ala-341. Moving outside the
crevice, water-mediated interactions of the remainder of the
agonist ligand with CCK1R are shorter lived, due to the faster
exchange of the bridging water molecules with the bulk
aqueous medium.
The original binding mode is virtually unperturbed as
water molecules propagate along in the crevice—a result that
is likely to stem from the strong anchoring of CCK9 at its
C-terminus, namely, Asp-8, and at its N-terminus, S-Tyr-3,
reinforced by steady van der Waals contacts formed between
both Met-7 and Phe-9 and the hydrophobic pocket. Alter-
native binding modes for other agonist or antagonist ligands,
and how water molecules mediate their association to
FIGURE 2 (A) Insight into the environment of the agonist ligand (left).
CCK9 is represented as a cyan surface, while interacting residues of CCK1R
brought to light experimentally are shown as green surfaces. Surrounding
water molecules are displayed as semitransparent spheres. Electrostatic
complementarity of the ligand and its receptor (right). Surfaces are colored
according to molecular electrostatic potentials. (B) Hydration pattern in the
binding site of CCK1R. CCK9 is depicted in a transparent van der Waals
envelope. (C) Indirect, water-mediated interactions of CCK9 with CCK1R.
Residues of the receptor are shown in a gray ball-and-stick representation.
Hydrogen bonds are highlighted as magenta dashed lines. The magenta
arrow points to the hydrogen bond formed between the amino group of
Phe-9 and a bridging water that interacts concomitantly with Thr-117 and
Thr-118.
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CCK1R should be considered in the light of the present
structural data. Of particular interest, the role played by the
vicinal Thr-117 and Thr-118 residues in the water-assisted
binding of ligands deserves further attention and should be
probed through site-directed mutagenesis experiments.
Receptor-ligand binding free energies
In terms of relation to experiment, the present MD simula-
tions essentially indicate whether or not the key protein-
ligand interactions are conserved through time. Free energy
calculations go one step beyond, by quantifying the impor-
tance of these interactions, and, hence, represent a tangible
thermodynamic measure for appraising the reliability of the
construct. Experimental and computed relative binding free
energies for the Asp-8 to Ala and S-Tyr-3 to Tyr point
mutations in CCK9 are gathered in Table 1.
The FEP estimate of13.06 0.7 kcal/mol for the Asp-8 to
Ala transformation agrees remarkably well with the binding-
afﬁnity assays experiments repeated up to six times, yielding
a free energy change of 13.2 6 0.3 kcal/mol. At the
microscopic level, replacement of Asp-8 by Ala is accom-
panied by subtle modiﬁcations in the crevice of CCK1R.
Around the middle of the mutation, i.e., l ¼ 0.5, Arg-336
pivots to interact with residue Thr-4 of CCK9. Interaction of
Asp-8 with Asn-333 is, however, preserved. Toward the end
of the transformation, the guanidinium moiety of Arg-336
forms a hydrogen bond with the amide group of Asn-333,
but the corresponding conformational modiﬁcations of the
side chains appear to be sufﬁciently limited to not perturb the
overall arrangement of the TM helices.
In silico replacement of S-Tyr-3 by Tyr led to an estimate
of 11.9 6 0.4 kcal/mol based on two different initial sets of
coordinates and momenta, whereas experiment predicts a
free energy change of 12.7 6 0.1 kcal/mol. During this
point mutation, binding of the tyrosyl residue to Arg-197
progressively weakens, as the level of hydration of the latter
increases. Though more ﬂexible than the lower end of the
binding pocket, the structure of the extracellular loops
remains essentially unperturbed by the alchemical transfor-
mation. This ﬂexibility, which can only be fully captured
over long timescales, is envisioned to affect the accuracy of
the simulation, thereby explaining the imperfect accord
between the theoretical and the experimental estimates of the
binding free energy difference, not necessarily reﬂected in
the statistical precision of the former. Reaching the desired
level of accuracy implies an appropriate description of slowly
relaxing phenomena, which, in most cases, constitutes a major
obstacle in free energy calculations of large, biologically rele-
vant systems, like membrane receptors. Another possible source
of error can be found in the suboptimal parameterization of the
nonstandard sulfated tyrosine residue.
Analysis of the convergence properties of the present
simulations indicates a smooth behavior of the free energy as
a function of l and converging ensemble averages for the
different l-intermediates between the initial and the ﬁnal
states of the alchemical transformation (see Fig. 3). Further-
more, conﬁgurational ensembles characteristic of contiguous
states appear to overlap very well, thereby satisfying a nec-
essary condition for appropriate convergence of FEP calcu-
lations (50).
Interestingly enough, compared to the FEP approach,
application of the acceptance ratio method of Bennett (50,51)
led to an agreement within 0.2 kcal/mol for the Asp-8 to Ala
mutation, thereby suggesting appropriate convergence of the
FEP ensemble averages. In the case of the S-Tyr-3 to Tyr
transformation, the differences in DG1mut and DG
2
mut are also
within 0.2 kcal/mol, but in opposite directions, thus yielding
a net binding free energy of12.2 kcal/mol, somewhat closer
to the target experimental value than the FEP estimate. It is
worth underlining that for both point mutations, the differ-
ence in the binding free energies between FEP and Bennett’s
approach is always less than the error estimate of the
calculation, which would imply that convergence properties
of the method is not a critical issue here. In contrast with the
error estimate reached from the simulations at 5.0 and 10.5
ns, the ﬁrst-order expansion only reﬂects the statistical
precision of the computation—namely, on the order of60.3
kcal/mol, which clearly does not account for ﬂuctuations in
the receptor-ligand structure over long timescales. It would,
therefore, appear that error estimates based on the statistical
properties of a single free energy calculation can be de-
ceiving, as they only provide the fraction of the total error
corresponding to the sampled region of the conﬁgurational
space. Arguably, relaxation along the slowest manifolds cannot
be captured in the ensemble averages, but comparison of the
latter in distinct simulations is expected to provide an appraisal
of the accuracy of the free energy calculations.
TABLE 1 Experimental and calculated relative binding free energies for the Asp-8 to Ala and S-Tyr-3 to Tyr point mutations in
agonist ligand CCK9
Experiment Theory
Point mutation Ki (WT) Ki (mut) DGbind DG
1
mut DG
2
mut DGbind
Asp-8/ Ala 1.38 6 0.15 253.8 6 11.4 13.2 6 0.3 1226.2 1229.2 13.0 6 0.7
S-Tyr-3/ Tyr 1.38 6 0.15 108.8 6 4.8 12.7 6 0.1 1181.1 1183.0 11.9 6 0.4
All experimental binding constants are in nanomoles, and free energies in kcal/mol. The notations utilized here are described in the thermodynamic cycle of
Fig. 2. Error estimates are obtained by repeating the free energy calculations with two different starting points, at 5 and 10.5 ns of the MD trajectory.
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CONCLUSIONS
The paucity of high-resolution structural information for mem-
brane proteins and, in particular, GPCRs, has opened new
vistas for molecular modeling. Among the methods that have
been devised to model GPCRs, the synergistic combination
of theory and experiment constitutes a promising perspective.
There is no guarantee, however, that a model built in vacuo
will behave similarly in a more relevant, heterogeneous
water-lipid medium (12).
In this contribution, the behavior of a three-dimensional
model of a GPCR (17) in an explicit membrane environment
has been probed by means of large-scale MD simulations.
Stability over 31 ns of the receptor-ligand complex embed-
ded in a POPC bilayer suggests that the system lies in a local
minimum of the conﬁgurational space, which satisﬁes the ex-
perimental restraints used to build the model. All-atom simu-
lations in realistic surroundings can be viewed as a reﬁnement
of the underlying physical criteria upon which the construct
is based, while preserving consistency with the body of ex-
perimental information. Whereas interpretation of binding-
afﬁnity measurements in terms of key interactions consti-
tutes an indirect link between experiment and theory, free
energy calculations open the way to a quantitative compar-
ison of biologically relevant properties of the system. The
very encouraging reproduction of relative binding free en-
ergies at the N- and the C-termini of agonist ligand CCK9
supports the view that the model complies with the exper-
imental observations employed in the process of its con-
struction (17). Enhancement of the model by means of an
explicit membrane environment offers new insight into the
role played by the solvent on the receptor-ligand complex.
Of particular interest, the diffusion of water molecules in the
binding pocket of CCK1R is not incompatible with the
binding mode predicted in the in vacuo construct. It further
highlights amino acids of the receptor with which the ligand
interacts indirectly by means of discrete water molecules.
Conﬁrming the role played by these residues in the formation
of the receptor-ligand complex to further understand how the
latter is mediated by internal water molecules is expected to
prompt new site-directed mutagenesis experiments. In turn,
improved characterization of the binding mode should
provide a valuable help in the design of potent agonist and
antagonist ligands.
Put together, the present results have increased our level of
conﬁdence in the original model, restrained to the properties
of the binding pocket and the TM a-helix bundle, thereby
paving the way to new hypotheses for interpreting available
structure-activity data. In this sense, it should be advocated
that the present molecular assembly, including the environ-
ment, be used for further studies, e.g., molecular docking of
alternate ligands, in particular in the framework of virtual
screening. To this effect, for completeness, the Cartesian
atomic coordinates of the receptor-ligand complex and its
internal water molecules are provided as Supplemental
Material. It still remains that the level of reliability in the
model of CCK1R is largely uneven, and markedly weaker in
the case of the intracellular loops, mostly due to the absence
of the G-protein subunits in the modeling of the latter.
Nevertheless, not only does the model reﬂect the exper-
imental observations utilized for its construction, but, more
importantly, it is capable of reproducing accurately thermo-
dynamic quantities that were not fed explicitly into the
modeling process. Among all the models of GPCRs
published hitherto, how many would actually fulﬁll these
criteria? It would be desirable that the simulation protocols
described herein be employed routinely for testing in vacuo
models before any further use.
The present strategy, however, is not expected to supply
a model of a GPCR closely matching its native three-
dimensional structure. Besides, it is far from evident to assess
how similar a model and a functional receptor are, inasmuch
as the structure has not been resolved experimentally.
Awaiting the release of high-resolution data, carefully devised
and tested models are anticipated to continue integrating new
information, and provide a reliable structural basis (52) that
can be utilized to advance our understanding of the function of
GPCRs and discover novel therapeutic agents.
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FIGURE 3 Evolution of the Gibbs free energy as a function of the coupling
parameter l. Here, the replacement of the S-Tyr-3 by tyrosine in CCK9 is
shown in the free and in the bound states, starting from a conﬁguration
obtained at 10.5 ns of the molecular dynamics (MD) trajectory. (Inset) Typical
overlap of conﬁgurational ensembles reﬂected in their respective density of
states, .ðEÞ; characteristic of contiguous intermediate states of the transfor-
mation, at l ¼ 0.5.
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